RU2036667C1 - Method for treating disseminated psoriasis - Google Patents
Method for treating disseminated psoriasis Download PDFInfo
- Publication number
- RU2036667C1 RU2036667C1 RU94002358A RU94002358A RU2036667C1 RU 2036667 C1 RU2036667 C1 RU 2036667C1 RU 94002358 A RU94002358 A RU 94002358A RU 94002358 A RU94002358 A RU 94002358A RU 2036667 C1 RU2036667 C1 RU 2036667C1
- Authority
- RU
- Russia
- Prior art keywords
- cryodestruction
- psoriasis
- treatment
- hemosorption
- cryotherapy
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Изобретение относится к медицине, в частности дерматологии, и предназначено для лечения псориаза. The invention relates to medicine, in particular dermatology, and is intended for the treatment of psoriasis.
Лечение псориаза включает большой арсенал средств и способов терапевтического, физиотерапевтического, физического воздействия, основанных на влиянии на патогенетические звенья данной патологии, а также носящих симптоматический характер. The treatment of psoriasis includes a large arsenal of means and methods of therapeutic, physiotherapeutic, and physical effects, based on the effect on the pathogenetic links of this pathology, as well as those of a symptomatic nature.
Одним из способов лечения псориаза в составе комплексного лечения является гемосорбция в различных вариантах (биогемосорбция путем перфузии крови больного через ксеноселезенку, гемосорбция в сочетании с гемодилюцией, ультрафильтрацией и оксигенацией). Однако при достаточной сложности и технической трудности не всегда удается получить стойкий терапевтический эффект. One of the methods of treating psoriasis as part of a comprehensive treatment is hemosorption in various forms (biohemosorption by perfusion of the patient’s blood through the xenosepleen, hemosorption in combination with hemodilution, ultrafiltration and oxygenation). However, with sufficient complexity and technical difficulty, it is not always possible to obtain a stable therapeutic effect.
Известен способ лечения псориаза, при котором осуществляют криодеструкцию псориатических высыпаний путем криоаппликаций жидким азотом при температуре ниже -100оС и экспозиции 5-30 с. При использовании данного способа, который является ближайшим аналогом, в условиях диссеминированной формы псориаза требуется длительный период лечения, который составляет от 2 до 4,5 месяцев (всего около 20 процедур с кратностью 3-5-7 дней). Это связано с тем, что в процессе криодеструкции происходит распад клеток эпидермиса и обработка больших площадей кожи приводит к угрозе развития интоксикации, поэтому секторальную обработку проводят с перерывами 3-7 дней, что при обширности поражения значительно удлиняет период лечения.A method of treating psoriasis, wherein cryodestruction performed by psoriatic lesions krioapplikatsy liquid nitrogen at a temperature below -100 ° C and 5-30 seconds exposure. When using this method, which is the closest analogue, in the conditions of a disseminated form of psoriasis, a long treatment period is required, which is from 2 to 4.5 months (a total of about 20 procedures with a multiplicity of 3-5-7 days). This is due to the fact that in the process of cryodestruction, the decomposition of epidermal cells occurs and treatment of large areas of the skin leads to the risk of intoxication, therefore, sectoral processing is carried out with interruptions of 3-7 days, which, with the extent of the lesion, significantly lengthens the treatment period.
В то же время, клинические наблюдения показали, что при криодеструкции эпидермиса в области псориатических бляшек в последующем после заживления нарушается рост волос. В эксперименте на морских свинках была показана избирательная высокая чувствительность волосяных фолликулов к воздействию жидким азотом и их необратимое повреждение. Это явилось основанием для проведения предварительной обработки кожи криопротекторами перед криовоздействием жидким азотом. Скорости диффузии криопротекторов в разные клетки сильно различаются. В эпидермисе достигается значительно меньшая концентрация, чем в фолликулах. При таком градиенте появляется возможность, с одной стороны, защитить волосяные фолликулы, с другой стороны, обеспечить достаточно жесткое криовоздействие на эпидермис. В качестве криопротекторов можно использовать различные вещества, в частности 70-80%-ный раствор глицерина или раствор, содержащий гликопептиды из сыворотки рыб. Как показал опыт их применения, криопротекцию следует начинать за 30-60-120 мин до криовоздействия. At the same time, clinical observations have shown that with cryodestruction of the epidermis in the area of psoriatic plaques, hair growth is subsequently disturbed after healing. In an experiment on guinea pigs, selective high sensitivity of hair follicles to exposure to liquid nitrogen and their irreversible damage was shown. This was the basis for pretreatment of the skin with cryoprotectants before cryotherapy with liquid nitrogen. The diffusion rates of cryoprotectors into different cells vary greatly. In the epidermis, a significantly lower concentration is achieved than in the follicles. With such a gradient, it is possible, on the one hand, to protect hair follicles, and on the other hand, to provide a sufficiently rigid cryogenic effect on the epidermis. Various substances can be used as cryoprotectants, in particular a 70-80% glycerol solution or a solution containing glycopeptides from fish serum. As experience with their use has shown, cryoprotection should begin 30-60-120 minutes before cryotherapy.
Криодеструкция обширных зон сопровождается значительной интоксикацией, что вынуждает удлинять период лечения за счет перерывов в лечении. Это явилось предпосылкой для использования метода гемосорбции с целью детоксикации организма, а за счет этого укорочения периода лечения. Таким образом, получаемый технический результат обусловлен совокупностью трех приемов криопротекции, криодеструкции и гемосорбции. Для криопротекции можно использовать любые средства, которые обладают такими свойствами; криовоздействие осуществляют в режимах, обеспечивающих деструкцию эпидермиса в области псориатических бляшек; гемосорбцию чередуют с криодеструкцией в режимах, достаточных для дезинтоксикации в зависимости от площади обрабатываемой кожи, сорбента и индивидуальных особенностей состояния больного. Cryodestruction of large areas is accompanied by significant intoxication, which forces to extend the treatment period due to interruptions in treatment. This was a prerequisite for using the hemosorption method to detoxify the body, and thereby shorten the treatment period. Thus, the obtained technical result is due to a combination of three methods of cryoprotection, cryodestruction and hemosorption. For cryoprotection, you can use any means that have such properties; cryotherapy is carried out in modes that ensure the destruction of the epidermis in the field of psoriatic plaques; hemosorption is alternated with cryodestruction in regimes sufficient for detoxification, depending on the area of the treated skin, the sorbent and the individual characteristics of the patient.
Способ осуществляют следующим образом. Перед сеансом криовоздействия производят обработку кожи в области тех псориатических очагов, которые будут подвергнуты воздействию на данном сеансе. Наносят раствор одного из протекторов за столько минут, сколько требуется для данного криопротектора. После этого осуществляют криодеструкцию по известному способу жидким азотом в течение 5-7 с в каждой точке выбранного сектора. Сеансы повторяют еще несколько дней в зависимости от обрабатываемой площади и состояния больного, в среднем, в течение трех суток. После этого проводят гемосорбцию в количестве 2-2,5 объема циркулирующей крови с использованием в качестве сорбента, например сорбента типа "ФАС", объемом колонки 400 см3. Затем в течение нескольких суток, в среднем около 10, больной не получает лечения, после перерыва лечение возобновляется с теми же приемами, но для других секторов тела.The method is as follows. Before a cryotherapy session, the skin is treated in the area of those psoriatic foci that will be exposed to this session. Apply a solution of one of the protectors in as many minutes as required for this cryoprotectant. After that, cryodestruction is carried out according to the known method with liquid nitrogen for 5-7 s at each point of the selected sector. Sessions are repeated for several more days, depending on the area being treated and the condition of the patient, on average, for three days. After that, hemosorption is carried out in an amount of 2-2.5 volumes of circulating blood using, for example, a sorbent of the "FAS" type as a sorbent, with a column volume of 400 cm 3 . Then for several days, on average, about 10, the patient does not receive treatment, after a break, treatment is resumed with the same techniques, but for other sectors of the body.
В амбулаторных условиях лечение проведено у 50 больных с диссеминированной формой псориаза. Весь период лечения и в последующем больные находились под наблюдением. Наибольший период наблюдения составляет до 1,5 лет. Имеющиеся клинические данные подтверждают высокую эффективность предложенного способа, достаточную простоту и отсутствие осложнений. Особенную ценность способ представляет для больных, которым не показаны те или иные терапевтические и другие методы лечения псориаза. On an outpatient basis, treatment was performed in 50 patients with disseminated form of psoriasis. The entire period of treatment and subsequently patients were monitored. The longest observation period is up to 1.5 years. Available clinical data confirm the high efficiency of the proposed method, sufficient simplicity and the absence of complications. Of particular value is the method for patients who are not shown certain therapeutic or other methods of treating psoriasis.
П р и м е р 1. Больная В. 31 год. Больна псориазом 17 лет. Процесс носил распространенный характер с преимущественной локализацией в области туловища и головы. Больная неоднократно лечилась амбулаторно с применением местных препаратов, витаминотерапии. Физиотерапевтическое лечение не показано из-за наличия противопоказания в виде миомы матки. Эффект от проводимого лечения незначителен. Проведено лечение предложенным способом в указанном режиме. Для осуществления способа потребовалось всего 18 дней. Лекарственная терапия была исключена полностью. В результате проведенного лечения полностью исчезли псориатические высыпания на коже головы и туловища. Последующие наблюдения в течение 1,5 лет не выявили обострений. PRI me R 1. Patient C. 31 years. Sick with psoriasis for 17 years. The process was widespread with predominant localization in the trunk and head. The patient was repeatedly treated on an outpatient basis using local drugs, vitamin therapy. Physiotherapeutic treatment is not indicated due to the presence of contraindications in the form of uterine fibroids. The effect of the treatment is negligible. The treatment of the proposed method in the specified mode. For the implementation of the method took only 18 days. Drug therapy was completely ruled out. As a result of the treatment, the psoriatic rashes on the scalp and trunk completely disappeared. Subsequent observations over 1.5 years did not reveal exacerbations.
П р и м е р 2. Больная Ц. 34 года. Больна псориазом 22 года, лечилась неоднократно, сопутствующие заболевания хронический тонзилит, мастопатия. Физиотерапевтические методы лечения противопоказаны. Проводимое лечение включало витаминотерапию, гемосорбцию. При этом эффективность лечения была незначительной. Псориаз носит диссеминированный характер, бляшки имеют размер 0,5-1,5 см в диаметре. Больной проведено лечение только с использованием криовоздействия. Из-за угрозы интоксикации сеансы проводились с перерывами (первые 2 недели 3 раза в неделю, затем 2 раза в неделю и 1 раз в неделю). Всего лечение потребовало 2 месяца, при этом была достигнута полная ремиссия. Однако, в области бывших псориатических бляшек имеются очаги облысения. PRI me R 2. Patient C. 34 years. Sick with psoriasis for 22 years, was treated repeatedly, concomitant diseases, chronic tonsillitis, mastopathy. Physiotherapeutic methods of treatment are contraindicated. The treatment included vitamin therapy, hemosorption. Moreover, the effectiveness of treatment was negligible. Psoriasis is disseminated in nature, plaques are 0.5-1.5 cm in diameter. The patient was treated only using cryotherapy. Because of the threat of intoxication, the sessions were held intermittently (the first 2 weeks 3 times a week, then 2 times a week and 1 time per week). In total, treatment took 2 months, while complete remission was achieved. However, in the area of former psoriatic plaques there are foci of baldness.
Таким образом, имеющийся клинический опыт показывает высокую эффективность предложенного способа лечения псориаза при снижении числа осложнений и укорочении периода лечения. Thus, the available clinical experience shows the high efficiency of the proposed method for the treatment of psoriasis while reducing the number of complications and shortening the treatment period.
Claims (4)
80% -ный водный раствор глицерина и наносят его на кожу за 30 60 мин до криовоздействия.2. The method according to claim 1, characterized in that 70 is used for cryoprotection
80% aqueous glycerol solution and apply it to the skin 30-60 minutes before cryotherapy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU94002358A RU2036667C1 (en) | 1994-01-24 | 1994-01-24 | Method for treating disseminated psoriasis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU94002358A RU2036667C1 (en) | 1994-01-24 | 1994-01-24 | Method for treating disseminated psoriasis |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2036667C1 true RU2036667C1 (en) | 1995-06-09 |
RU94002358A RU94002358A (en) | 1996-07-10 |
Family
ID=20151702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU94002358A RU2036667C1 (en) | 1994-01-24 | 1994-01-24 | Method for treating disseminated psoriasis |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2036667C1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9314368B2 (en) | 2010-01-25 | 2016-04-19 | Zeltiq Aesthetics, Inc. | Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associates devices, systems and methods |
US9375345B2 (en) | 2006-09-26 | 2016-06-28 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US9545523B2 (en) | 2013-03-14 | 2017-01-17 | Zeltiq Aesthetics, Inc. | Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue |
USD777338S1 (en) | 2014-03-20 | 2017-01-24 | Zeltiq Aesthetics, Inc. | Cryotherapy applicator for cooling tissue |
US9655770B2 (en) | 2007-07-13 | 2017-05-23 | Zeltiq Aesthetics, Inc. | System for treating lipid-rich regions |
US9737434B2 (en) | 2008-12-17 | 2017-08-22 | Zeltiq Aestehtics, Inc. | Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells |
US9844460B2 (en) | 2013-03-14 | 2017-12-19 | Zeltiq Aesthetics, Inc. | Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same |
US9861520B2 (en) | 2009-04-30 | 2018-01-09 | Zeltiq Aesthetics, Inc. | Device, system and method of removing heat from subcutaneous lipid-rich cells |
US9861421B2 (en) | 2014-01-31 | 2018-01-09 | Zeltiq Aesthetics, Inc. | Compositions, treatment systems and methods for improved cooling of lipid-rich tissue |
US10092346B2 (en) | 2010-07-20 | 2018-10-09 | Zeltiq Aesthetics, Inc. | Combined modality treatment systems, methods and apparatus for body contouring applications |
US10383787B2 (en) | 2007-05-18 | 2019-08-20 | Zeltiq Aesthetics, Inc. | Treatment apparatus for removing heat from subcutaneous lipid-rich cells and massaging tissue |
US10524956B2 (en) | 2016-01-07 | 2020-01-07 | Zeltiq Aesthetics, Inc. | Temperature-dependent adhesion between applicator and skin during cooling of tissue |
US10555831B2 (en) | 2016-05-10 | 2020-02-11 | Zeltiq Aesthetics, Inc. | Hydrogel substances and methods of cryotherapy |
US10568759B2 (en) | 2014-08-19 | 2020-02-25 | Zeltiq Aesthetics, Inc. | Treatment systems, small volume applicators, and methods for treating submental tissue |
US10675176B1 (en) | 2014-03-19 | 2020-06-09 | Zeltiq Aesthetics, Inc. | Treatment systems, devices, and methods for cooling targeted tissue |
US10675178B2 (en) | 2007-08-21 | 2020-06-09 | Zeltiq Aesthetics, Inc. | Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue |
US10682297B2 (en) | 2016-05-10 | 2020-06-16 | Zeltiq Aesthetics, Inc. | Liposomes, emulsions, and methods for cryotherapy |
US10722395B2 (en) | 2011-01-25 | 2020-07-28 | Zeltiq Aesthetics, Inc. | Devices, application systems and methods with localized heat flux zones for removing heat from subcutaneous lipid-rich cells |
US10765552B2 (en) | 2016-02-18 | 2020-09-08 | Zeltiq Aesthetics, Inc. | Cooling cup applicators with contoured heads and liner assemblies |
US10935174B2 (en) | 2014-08-19 | 2021-03-02 | Zeltiq Aesthetics, Inc. | Stress relief couplings for cryotherapy apparatuses |
US10952891B1 (en) | 2014-05-13 | 2021-03-23 | Zeltiq Aesthetics, Inc. | Treatment systems with adjustable gap applicators and methods for cooling tissue |
US11076879B2 (en) | 2017-04-26 | 2021-08-03 | Zeltiq Aesthetics, Inc. | Shallow surface cryotherapy applicators and related technology |
US11154418B2 (en) | 2015-10-19 | 2021-10-26 | Zeltiq Aesthetics, Inc. | Vascular treatment systems, cooling devices, and methods for cooling vascular structures |
US11382790B2 (en) | 2016-05-10 | 2022-07-12 | Zeltiq Aesthetics, Inc. | Skin freezing systems for treating acne and skin conditions |
US11395760B2 (en) | 2006-09-26 | 2022-07-26 | Zeltiq Aesthetics, Inc. | Tissue treatment methods |
US11446175B2 (en) | 2018-07-31 | 2022-09-20 | Zeltiq Aesthetics, Inc. | Methods, devices, and systems for improving skin characteristics |
US11986421B2 (en) | 2006-09-26 | 2024-05-21 | Zeltiq Aesthetics, Inc. | Cooling devices with flexible sensors |
US12070411B2 (en) | 2006-04-28 | 2024-08-27 | Zeltiq Aesthetics, Inc. | Cryoprotectant for use with a treatment device for improved cooling of subcutaneous lipid-rich cells |
-
1994
- 1994-01-24 RU RU94002358A patent/RU2036667C1/en active
Non-Patent Citations (1)
Title |
---|
Патент РФ N 2000088, кл. A 61B 17/36, 1993. * |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12070411B2 (en) | 2006-04-28 | 2024-08-27 | Zeltiq Aesthetics, Inc. | Cryoprotectant for use with a treatment device for improved cooling of subcutaneous lipid-rich cells |
US11395760B2 (en) | 2006-09-26 | 2022-07-26 | Zeltiq Aesthetics, Inc. | Tissue treatment methods |
US9375345B2 (en) | 2006-09-26 | 2016-06-28 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US11986421B2 (en) | 2006-09-26 | 2024-05-21 | Zeltiq Aesthetics, Inc. | Cooling devices with flexible sensors |
US11179269B2 (en) | 2006-09-26 | 2021-11-23 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US11219549B2 (en) | 2006-09-26 | 2022-01-11 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US10292859B2 (en) | 2006-09-26 | 2019-05-21 | Zeltiq Aesthetics, Inc. | Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile |
US11291606B2 (en) | 2007-05-18 | 2022-04-05 | Zeltiq Aesthetics, Inc. | Treatment apparatus for removing heat from subcutaneous lipid-rich cells and massaging tissue |
US10383787B2 (en) | 2007-05-18 | 2019-08-20 | Zeltiq Aesthetics, Inc. | Treatment apparatus for removing heat from subcutaneous lipid-rich cells and massaging tissue |
US9655770B2 (en) | 2007-07-13 | 2017-05-23 | Zeltiq Aesthetics, Inc. | System for treating lipid-rich regions |
US11583438B1 (en) | 2007-08-21 | 2023-02-21 | Zeltiq Aesthetics, Inc. | Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue |
US10675178B2 (en) | 2007-08-21 | 2020-06-09 | Zeltiq Aesthetics, Inc. | Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue |
US9737434B2 (en) | 2008-12-17 | 2017-08-22 | Zeltiq Aestehtics, Inc. | Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells |
US11452634B2 (en) | 2009-04-30 | 2022-09-27 | Zeltiq Aesthetics, Inc. | Device, system and method of removing heat from subcutaneous lipid-rich cells |
US9861520B2 (en) | 2009-04-30 | 2018-01-09 | Zeltiq Aesthetics, Inc. | Device, system and method of removing heat from subcutaneous lipid-rich cells |
US11224536B2 (en) | 2009-04-30 | 2022-01-18 | Zeltiq Aesthetics, Inc. | Device, system and method of removing heat from subcutaneous lipid-rich cells |
US9314368B2 (en) | 2010-01-25 | 2016-04-19 | Zeltiq Aesthetics, Inc. | Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associates devices, systems and methods |
US9844461B2 (en) | 2010-01-25 | 2017-12-19 | Zeltiq Aesthetics, Inc. | Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants |
US10092346B2 (en) | 2010-07-20 | 2018-10-09 | Zeltiq Aesthetics, Inc. | Combined modality treatment systems, methods and apparatus for body contouring applications |
US10722395B2 (en) | 2011-01-25 | 2020-07-28 | Zeltiq Aesthetics, Inc. | Devices, application systems and methods with localized heat flux zones for removing heat from subcutaneous lipid-rich cells |
US9844460B2 (en) | 2013-03-14 | 2017-12-19 | Zeltiq Aesthetics, Inc. | Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same |
US9545523B2 (en) | 2013-03-14 | 2017-01-17 | Zeltiq Aesthetics, Inc. | Multi-modality treatment systems, methods and apparatus for altering subcutaneous lipid-rich tissue |
US10575890B2 (en) | 2014-01-31 | 2020-03-03 | Zeltiq Aesthetics, Inc. | Treatment systems and methods for affecting glands and other targeted structures |
US10912599B2 (en) | 2014-01-31 | 2021-02-09 | Zeltiq Aesthetics, Inc. | Compositions, treatment systems and methods for improved cooling of lipid-rich tissue |
US10201380B2 (en) | 2014-01-31 | 2019-02-12 | Zeltiq Aesthetics, Inc. | Treatment systems, methods, and apparatuses for improving the appearance of skin and providing other treatments |
US9861421B2 (en) | 2014-01-31 | 2018-01-09 | Zeltiq Aesthetics, Inc. | Compositions, treatment systems and methods for improved cooling of lipid-rich tissue |
US10806500B2 (en) | 2014-01-31 | 2020-10-20 | Zeltiq Aesthetics, Inc. | Treatment systems, methods, and apparatuses for improving the appearance of skin and providing other treatments |
US11819257B2 (en) | 2014-01-31 | 2023-11-21 | Zeltiq Aesthetics, Inc. | Compositions, treatment systems and methods for improved cooling of lipid-rich tissue |
US10675176B1 (en) | 2014-03-19 | 2020-06-09 | Zeltiq Aesthetics, Inc. | Treatment systems, devices, and methods for cooling targeted tissue |
USD777338S1 (en) | 2014-03-20 | 2017-01-24 | Zeltiq Aesthetics, Inc. | Cryotherapy applicator for cooling tissue |
US10952891B1 (en) | 2014-05-13 | 2021-03-23 | Zeltiq Aesthetics, Inc. | Treatment systems with adjustable gap applicators and methods for cooling tissue |
US10568759B2 (en) | 2014-08-19 | 2020-02-25 | Zeltiq Aesthetics, Inc. | Treatment systems, small volume applicators, and methods for treating submental tissue |
US10935174B2 (en) | 2014-08-19 | 2021-03-02 | Zeltiq Aesthetics, Inc. | Stress relief couplings for cryotherapy apparatuses |
US11154418B2 (en) | 2015-10-19 | 2021-10-26 | Zeltiq Aesthetics, Inc. | Vascular treatment systems, cooling devices, and methods for cooling vascular structures |
US10524956B2 (en) | 2016-01-07 | 2020-01-07 | Zeltiq Aesthetics, Inc. | Temperature-dependent adhesion between applicator and skin during cooling of tissue |
US10765552B2 (en) | 2016-02-18 | 2020-09-08 | Zeltiq Aesthetics, Inc. | Cooling cup applicators with contoured heads and liner assemblies |
US10555831B2 (en) | 2016-05-10 | 2020-02-11 | Zeltiq Aesthetics, Inc. | Hydrogel substances and methods of cryotherapy |
US10682297B2 (en) | 2016-05-10 | 2020-06-16 | Zeltiq Aesthetics, Inc. | Liposomes, emulsions, and methods for cryotherapy |
US11382790B2 (en) | 2016-05-10 | 2022-07-12 | Zeltiq Aesthetics, Inc. | Skin freezing systems for treating acne and skin conditions |
US11076879B2 (en) | 2017-04-26 | 2021-08-03 | Zeltiq Aesthetics, Inc. | Shallow surface cryotherapy applicators and related technology |
US11446175B2 (en) | 2018-07-31 | 2022-09-20 | Zeltiq Aesthetics, Inc. | Methods, devices, and systems for improving skin characteristics |
US12102557B2 (en) | 2018-07-31 | 2024-10-01 | Zeltiq Aesthetics, Inc. | Methods, devices, and systems for improving skin characteristics |
Also Published As
Publication number | Publication date |
---|---|
RU94002358A (en) | 1996-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2036667C1 (en) | Method for treating disseminated psoriasis | |
Veltkamp et al. | Hyperbaric oxygen decreases infarct size and behavioral deficit after transient focal cerebral ischemia in rats | |
Murray et al. | Keloids: a review | |
Hupkens et al. | Tannic acid as a topical agent in burns: historical considerations and implications for new developments | |
Yamazaki et al. | Linear polarized infrared irradiation using Super Lizer™ is an effective treatment for multiple‐type alopecia areata | |
Foley | Clinical efficacy of methyl aminolevulinate (Metvix®) photodynamic therapy | |
de CAMARA et al. | Ultrastructural aspects of cooled thermal injury | |
Hirose et al. | Topical treatment of resistant warts with glutaraldehyde | |
DK47089A (en) | SUBSTANCE WITH DAMAGING EFFECT ON TIMAL TUMORS, PROCEDURES FOR THE PREPARATION OF SUCH AGENTS AND THE USE OF THESE FOR THERAPEUTIC TREATMENT OF CANCER | |
Abd-el-Raheem et al. | Granuloma pyogenicum as a Complication of FlashIamp-Pumped Pulsed Dye Laser | |
Levitt et al. | The effects of subarachnoid blood on the electrocorticogram of the cat | |
Morrone et al. | In Vitro Experimental Research of Rabbit Condrocytes Biostimulation with Diode Laser Ga-Ai-As: A Preliminary Study | |
RU2296595C2 (en) | Method for treating patients with laser radiation | |
KUFLIK | Cryosurgical treatment of periungual warts | |
WAKIM | Ultrasonic energy as applied to medicine | |
Chan et al. | Accelerated healing of carbon dioxide laser burns in rats treated with composite polyurethane dressings | |
Ruocco | Plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris: a novelty or a reappraisal? | |
Erkens et al. | Treatment of verrucae vulgares in general practice—a randomized controlled trial on the effectiveness of liquid nitrogen and the Histofreezer | |
RU2823154C1 (en) | Method of treating non-scarring alopecia | |
CN114558113B (en) | Transforming growth factor-alpha spray for treating mild scald and preparation method thereof | |
DE3276786D1 (en) | Medical process and preparation | |
Levine et al. | Radiofrequency hyperthermia and topical retinoic acid therapy in murine melanoma | |
RU2181591C2 (en) | Method of preparing substance for destruction of microcirculatory alveus of topical cutaneous formations | |
Adams et al. | Excision of cutaneous tumors in the horse using histologic guidance | |
RU2121378C1 (en) | Method for treating the cases of urolithiasis |